The Present and FutureJACC State-of-the-Art ReviewTransthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Ruberg is supported by the National Institutes of Health (NIH) (grants HL139671-01 and AG 050206-02). Dr. Kelly is supported by the NIH (grant DK46335). Dr. Maurer is supported by the NIH (grants R01HL139671-01, R21AG058348 and K24AG036778). Dr. Ruberg has received support from Eidos Therapeutics; and has received consulting fees from Pfizer and GlaxoSmithKline. Dr. Grogan has taken part in clinical trials for Alnylam, Eidos, Pfizer, and Prothena; and has been a consultant to Alnylam, Eidos, Pfizer, Prothena, and Akcea. Dr. Kelly has received consulting, equity, and royalty fees from Pfizer linked to Tafamidis sales; is the founder of Fold Rx and Proteostasis Therapeutics; and has been a consultant, shareholder, and board member of Proteostasis Therapeutics. Dr. Hanna has taken part in clinical trials for Pfizer, Alnylam, and Akcea; and has been a consultant and a member of the Advisory Board for Pfizer, Alnylam, Akcea, and Eidos. Dr. Maurer has received consulting fees from Pfizer, GlaxoSmithKline, EIdos, Prothena, Akcea, and Alnylam; and has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam.
Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.